Glaukos (NYSE:GKOS) shares ticked up this morning on first-quarter results that came in mixed compared to the consensus forecast. Shares of GKOS rose 9% at $50.66 apiece as the market opened today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — dipped 0.03%. The (LOCATION)-based company posted losses […]
Glaukos
Celanese to provide drug delivery platform for Glaukos glaucoma treatment
Celanese (NYSE:CE) announced today that it entered into an agreement with Glaukos (NYSE:GKOS) over drug delivery for glaucoma treatments. Dallas-based Celanese agreed to supply its VitalDose drug delivery platform for use as a component in Gluakos’ iDose TR. The iDose TR serves as a micro-invasive intraocular implant for lowering intraocular pressure. It treats patients with […]
Glaukos submits FDA New Drug Application for iDose TR drug-eluting implant
Glaukos (NYSE:GKOS) announced today that it submitted a New Drug Application (NDA) to the FDA for its iDose TR implant. Aliso Viejo, California-based Glaukos designed iDose TR as a micro-invasive intraocular implant. It continuously delivers therapeutic levels of a proprietary formulation of travoprost from within the eye over extended periods of time. Once all travoprost […]
Glaukos beats The Street in Q4
Glaukos (NYSE:GKOS) shares took a hit today despite fourth-quarter results that topped the consensus forecast. Shares of GKOS dipped 7% at $46.90 apiece in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 8.1%. The Aliso Viejo, California-based ophthalmic implant maker posted losses of […]
Glaukos beats The Street in Q3
Glaukos (NYSE:GKOS) shares hardly shifted on third-quarter results that came in ahead of the consensus forecast. The Aliso Viejo, California-based ophthalmic implant maker posted losses of $27.6 million in the quarter. That amounts to 58¢ per share on sales of $71.3 million for the three months ended Sept. 30, 2022. Get the full story at […]
5 top ophthalmic device innovations you need to know
Innovation finds its way into all areas of medtech, and ophthalmic treatments represent another burgeoning space. It may not be a new wave, but medtech companies continue to improve upon technologies for the human eye. Implants, lenses and more comprise the space’s latest innovations, with a number of companies finding new ways to fix old […]
Phase 3 trial data support Glaukos iDose eye drop alternative
Glaukos (NYSE:GKOS) today announced positive outcomes from two Phase 3 pivotal trials for its iDose TR system. iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP). Glaukos designed it to continuously release therapeutic levels of medication for at least one year. Once all travoprost is released, iDose […]
Glaukos stock dips on big Q2 earnings miss
Glaukos (NYSE:GKOS) shares were down this morning on second-quarter results that missed the consensus earnings forecast. The Aliso Viejo, California–based glaucoma treatment developer posted losses of $45.5 million, or 96¢ per share, on sales of $72.7 million for the three months ended June 30, 2022, for a bottom-line slide deeper into the red on a […]
Glaukos posts Street-beating Q1 results
Glaukos (NYSE:GKOS) this week posted first-quarter results that beat the overall consensus on Wall Street. The San Clemente, California-based company reported profits of $5.4 million, or 11¢ per share, on sales of $67.7 million for the three months ended March 31, for a sales loss of -0.42% compared with Q1 2021. Adjusted to exclude one-time items, […]
Glaukos rises on Street-beating Q4
Glaukos (NYSE:GKOS) shares ticked up today on fourth-quarter results that beat the consensus forecast. The San Clemente, California-based eye disease treatment developer posted losses of $21.9 million, or losses per share of 47¢, on sales of $73.2 million for the three months ended Dec. 31, 2021, for a bottom-line slide deeper into the red on […]
Glaukos announces executive leadership changes
Glaukos this week announced several executive leadership changes that will take place on April 1. Joseph Gilliam is appointed as president and COO. He previously served as the CFO and SVP of corporate development for the San Clemente, California-based ophthalmic medtech and pharma company since 2017. Here are Glaukos’ new executive committee appointments: Chris Calcaterra […]
